US4443549A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Production of monoclonal antibodies against bacterial adhesins
Assignee: MGI Pharma Inc
•
Filing: 1982-10-07
•
Granted: 1984-04-17
•
Expires: 2002-10-07
Abstract
Abstract Monoclonal antibodies specific for surface antigens of bacteria which act as adhesins between prokaryotic and eukaryotic cells and, in particular, K-99 pili, and methods for production thereof are described. These monoclonal antibodies may be used for the prophylactic and therapeutic treatment of diseases induced by adhesin-bearing pathogens in animals and humans, and for the diagnostic identification of adhesin-bearing bacteria.
Inventors
- 👤 Peter L. Sadowski
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 02:18
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/195; C07K14/24; C07K14/245; C07K16/00; C07K16/12; C07K16/1203; C07K16/1228; C07K16/1232; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/848; Y10S435/849; Y10S435/874; Y10S435/875; Y10S530/00; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 52
Claim 1
Independent Claim
65 words
A process for producing monoclonal antibodies against an adhesion of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: propagating a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, with a myeloma cell and harvesting the antibodies produced by said hybridoma.
Claim 2
Dependent Claim
65 words
A process for producing monoclonal antibodies against an adhesion of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: propagating a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, with a myeloma cell and harvesting the antibodies produced by said hybridoma.
Claim 3
Dependent Claim
12 words
The process of claim 1 wherein said adhesin is a protein adhesin.
Claim 4
Dependent Claim
11 words
The process of claim 1 wherein said adhesin is a pilus.
Claim 5
Dependent Claim
12 words
The process of claim 1 wherein said adhesin is a glycocalyx polysaccharide.
Claim 6
Dependent Claim
12 words
The process of claim 1 wherein said hybridoma is propagated in vitro.
Claim 7
Dependent Claim
12 words
The process of claim 1 wherein said hybridoma is propagated in vivo.
Claim 8
Dependent Claim
32 words
The process of claim 1 wherein said cell capable of producing antibodies against an adhesin of a pathogenic bacterium is selected from the group consisting of spleen cells and lymph node cells.
Claim 9
Dependent Claim
17 words
The process of claim 7 wherein said spleen is mouse spleen and said myeloma is mouse myeloma.
Claim 10
Dependent Claim
43 words
The process of claim 1 wherein said cell capable of producing antibodies against an adhesin of a pathogenic bacterium is obtained from an animal immunized with a pilus adhesin, an immunogenic fragment thereof, or a bacterium, or part thereof, bearing a pilus adhesin.
Claim 11
Dependent Claim
43 words
The process of claim 1 wherein said cell capable of producing antibodies against an adhesin of a pathogenic bacterium is obtained from an animal immunized with a glycocalyx adhesin, an immunogenic fragment thereof, or a bacterium, or part thereof, bearing a glycocalyx adhesin.
Claim 12
Dependent Claim
11 words
The process of claim 1 wherein the bacterium is Escherichia coli.
Claim 13
Dependent Claim
11 words
The process of claim 1 wherein the bacterium is Pseudomonas aeruginosa.
Claim 14
Dependent Claim
23 words
The process of claim 3 wherein the pilus is selected from the group consisting of K-99, K-88, 987P, F41, CFA/I and CFA/II pili.
Claim 15
Dependent Claim
11 words
The process of claim 3 wherein the pilus is K-99 pilus.
Claim 16
Dependent Claim
96 words
A process for producing monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: (a) propagating a hybridoma (i) formed by fusing a P3/NSI/1-Ag4-1 myeloma cell with a murine cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, said murine cell having been obtained from a BALB/c mouse immunized with a bacterial adhesion and (ii) isolated after in vitro culturing in selective HAT medium; and (b) harvesting the antibodies produced by said hybridoma.
Claim 17
Dependent Claim
96 words
A process for producing monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: (a) propagating a hybridoma (i) formed by fusing a P3/NSI/1-Ag4-1 myeloma cell with a murine cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, said murine cell having been obtained from a BALB/c mouse immunized with a bacterial adhesion and (ii) isolated after in vitro culturing in selective HAT medium; and (b) harvesting the antibodies produced by said hybridoma.
Claim 18
Dependent Claim
12 words
The process of claim 15 wherein said hybridoma is propagated in vitro.
Claim 19
Dependent Claim
12 words
The process of claim 15 wherein said hybridoma is propagated in vivo.
Claim 20
Dependent Claim
12 words
The process of claim 15 wherein said adhesin is the K-99 pilus.
Claim 21
Dependent Claim
58 words
A continuous cell line which produces monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, with a myeloma cell.
Claim 22
Dependent Claim
58 words
A continuous cell line which produces monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, with a myeloma cell.
Claim 23
Dependent Claim
12 words
The cell line of claim 19 wherein said adhesin is a pilus.
Claim 24
Dependent Claim
12 words
The cell line of claim 19 wherein said adhesin is K-99 pilus.
Claim 25
Dependent Claim
41 words
Hybridoma cell line 2BD4E4, ATCC Number HB8178, formed by fusing a P3/NSI/1-Ag 4-1 murine myeloma cell with a murine spleen cell obtained from a BALB/c mouse immunized with K-99 pili, which hybridoma cell line produces monoclonal antibodies against a K-99 pilus.
Claim 26
Dependent Claim
41 words
Hybridoma cell line 2BD4E4, ATCC Number HB8178, formed by fusing a P3/NSI/1-Ag 4-1 murine myeloma cell with a murine spleen cell obtained from a BALB/c mouse immunized with K-99 pili, which hybridoma cell line produces monoclonal antibodies against a K-99 pilus.
Claim 27
Dependent Claim
13 words
The cell line of claim 19 wherein said adhesin is a protein adhesin.
Claim 28
Dependent Claim
13 words
The cell line of claim 19 wherein said adhesin is a glycocalyx polysaccharide.
Claim 29
Dependent Claim
19 words
Monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue.
Claim 30
Dependent Claim
19 words
Monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue.
Claim 31
Dependent Claim
13 words
Monoclonal antibodies against K-99 pilus produced by the cell line of claim 22.
Claim 32
Dependent Claim
28 words
A pharmaceutical composition comprising monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, and a pharmaceutical carrier therefor.
Claim 33
Dependent Claim
28 words
A pharmaceutical composition comprising monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, and a pharmaceutical carrier therefor.
Claim 34
Dependent Claim
12 words
The pharmaceutical composition of claim 27, wherein the adhesin is a pilus.
Claim 35
Dependent Claim
13 words
The pharmaceutical composition of claim 27, wherein the adhesin is a protein adhesin.
Claim 36
Dependent Claim
13 words
The pharmaceutical composition of claim 27, wherein the adhesin is a glycocalyx polysaccharide.
Claim 37
Dependent Claim
17 words
The pharmaceutical composition of claim 27, wherein the pharmaceutical carrier is suitable for oral administration to animals.
Claim 38
Dependent Claim
17 words
The pharmaceutical composition of claim 28, wherein the pharmaceutical carrier is suitable for oral administration to animals.
Claim 39
Dependent Claim
14 words
The pharmaceutical composition of claim 31 or 32, wherein said carrier is maternal colostrum.
Claim 40
Dependent Claim
18 words
The pharmaceutical composition of claim 31 or 32, wherein said carrier is Tris buffer containing bovine serum albumin.
Claim 41
Dependent Claim
14 words
The pharmaceutical composition of claim 31 or 32, wherein said carrier is skimmed milk.
Claim 42
Dependent Claim
20 words
The pharmaceutical composition of claim 31 wherein said animals are selected from the group consisting of calves, lambs and piglets.
Claim 43
Dependent Claim
18 words
The pharmaceutical composition of claim 27, wherein the pharmaceutical carrier is suitable for topical administration to a host.
Claim 44
Dependent Claim
21 words
The pharmaceutical composition of claim 27, wherein the pharmaceutical carrier is suitable for administration to the respiratory tract of a host.
Claim 45
Dependent Claim
86 words
A process for producing monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: propagating a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue, with a myeloma cell and harvesting the antibodies produced by said hybridoma.
Claim 46
Dependent Claim
86 words
A process for producing monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising: propagating a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue, with a myeloma cell and harvesting the antibodies produced by said hybridoma.
Claim 47
Dependent Claim
13 words
The process of claim 39 wherein the mucocutaneous tissue is mammalian intestinal lining.
Claim 48
Dependent Claim
40 words
Monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue.
Claim 49
Dependent Claim
40 words
Monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue.
Claim 50
Dependent Claim
14 words
The monoclonal antibodies of claim 41 wherein the mucocutaneous tissue is mammalian intestinal lining.
Claim 51
Dependent Claim
80 words
A continuous cell line which produces monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates the attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue, with a myeloma cell.
Claim 52
Dependent Claim
80 words
A continuous cell line which produces monoclonal antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates attachment of said bacterium to mucocutaneous tissue, comprising a hybridoma formed by fusing a cell capable of producing antibodies against an adhesin of a pathogenic bacterium, which adhesin mediates the attachment of said bacterium to mucocutaneous tissue, the pathogenicity of said bacterium being dependent on noninvasive, adhesin-mediated attachment to and subsequent proliferation on the surface of mucocutaneous tissue, with a myeloma cell.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-17 | 1987-10-17 | 1988-04-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-17 | 1991-10-17 | 1992-04-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-17 | 1995-10-17 | 1996-04-17 | $7700.00 | Window Closed / Lapsed |